Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Бронхоэктазы у взрослых больных: клинические рекомендации Европейского респираторного общества


https://doi.org/10.18093/0869-0189-2018-28-2-147-168

Полный текст:


Аннотация

Бронхоэктазы (БЭ) у взрослых – это хроническое заболевание, связанное с низким качеством жизни (КЖ), а в большинстве случаев – с частыми обострениями. До настоящего времени международные клинические рекомендации по этой проблеме отсутствовали. В клинических рекомендациях Европейского респираторного общества по ведению взрослых пациентов с БЭ содержатся описания клинических исследований и терапевтического подхода, основанного на систематическом обзоре опубликованных данных. Экспертами многопрофильной группы, состоящей из пульмонологов, микробиологов, специалистов по лечебной физкультуре, торакальных хирургов, врачей первичного звена, методистов и пациентов, отобраны 9 наиболее важных (как для врачей, так и для пациентов) клинических проблем, относящихся к теме БЭ. По этим проблемам в литературе проведен поиск клинических и наблюдательных исследований, а также систематических обзоров, на основании которых выполнен систематический обзор. Для определения качества доказательств и уровня рекомендаций использовалась система GRADE. В данных клинических рекомендациях рассматриваются вопросы установления этиологии БЭ, терапии обострений, эрадикации возбудителей, длительной антибактериальной, противовоспалительной, мукоактивной и бронхолитической терапии, хирургического лечения и лечебной физкультуры. Данные рекомендации могут применяться для сравнительной оценки КЖ лиц с БЭ в странах Европы и улучшения исходов указанного заболевания.

Об авторе

статья Редакционная

Россия


Список литературы

1. Winter D.H., Manzini M., Salge J.M. et al. Aging of the lungs in asymptomatic lifelong nonsmokers: findings on. HRCT. Lung. 2015; 193 (2): 283–290. DOI: 10.1007/s00408-015-9700-3.

2. Brozek J.L., Akl E.A., Compalati E. et al. Grading quality of evidence and strength of recommendations in clinical practice guidelinesPart 3 of 3. The GRADE approach to developingrecommendations. Allergy. 2011; 66 (5): 588–595. DOI: 10.1111/j.1398-9995.2010.02530.x.

3. Andrews J., Guyatt G., Oxman A.D. et al. GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. J. Clin. Epidemiol. 2013; 66 (7): 719–725. DOI: 10.1016/j.jclinepi.2012.03.013.

4. King P.T., Holdsworth S.R., Freezer N.J. et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir. Med. 2006; 100 (12): 2183–2189. DOI: 10.1016/j.rmed.2006.03.012.

5. Raghu G., King T.E., Behr J. et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur. Respir. J. 2010; 35 (1): 118–123. DOI: 10.1183/09031936.00188108.

6. Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554. DOI: 10.1056/NEJMoa0805800.

7. Chalmers J.D., Smith M.P., McHugh B.J. et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2012; 186 (7): 657–665. DOI: 10.1164/rccm.201203-0487OC.

8. Sheehan R.E., Wells A.U., Copley S.J. et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur. Respir. J. 2002; 20: 581–587. DOI: 10.1183/09031936.02.00284602.

9. Chalmers J.D., Goeminne P., Aliberti S. et al. The bronchiectasis severity index. An international derivation and validation study. Am. J. Respir. Crit. Care Med. 2014; 189 (5): 576–585. DOI: 10.1164/rccm.201309-1575OC.

10. Aliberti S., Lonni S., Dore S. et al. Clinical phenotypes in adult patients with bronchiectasis. Eur. Respir. J. 2016; 47 (4): 1113–1122. DOI: 10.1183/13993003.01899-2015.

11. Kapur N., Masters I.B., Chang A.B. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: What influences lung function stability? Chest. 2010; 138 (1): 158–164. DOI: 10.1378/chest.09-2932.

12. Chalmers J.D., Aliberti S., Polverino E. et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Res. 2016; 2 (1): 00081–2015. DOI: 10.1183/23120541.00081-2015.

13. Loebinger M.R., Wells A.U., Hansell D.M. et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur. Respir. J. 2009; 34 (4): 843–849. DOI: 10.1183/09031936.00003709.

14. McDonnell M.J., Aliberti S., Goeminne P.C. et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016; 71 (12): 1110–1118. DOI: 10.1136/thoraxjnl-2016-208481.

15. Finch S., McDonnell M.J., Abo-Leyah H. et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 2015; 12 (11): 1602–1611. DOI: 10.1513/AnnalsATS.201506-333OC.

16. Wilson C.B., Jones P.W., O’Leary C.J. et al. Systemic markers of inflammation in stable bronchiectasis. Eur. Respir. J. 1998; 12 (4): 820–824. DOI: 10.1183/09031936.98.12040820.

17. Tsang K.W., Chan K.N., Ho P.L. et al. Sputum elastase in steady-state bronchiectasis. Chest. 2000; 117 (2): 420–426. DOI: 10.1378/chest.117.2.420.

18. Chalmers J.D., Moffitt K.L., Suarez-Cuartin G. et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am. J. Respir. Crit. Care Med. 2017; 195 (10): 1384–1393. DOI: 10.1164/rccm.201605-1027OC.

19. Chalmers J.D., Hill A.T. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol. Immunol. 2013; 55 (1): 27–34. DOI: 10.1016/j.molimm.2012.09.011.

20. Snijders D., Dominguez B.F., Calgaro S. et al. Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence? Int. J. Immunopathol. Pharmacol. 2015; 28 (2): 150–159. DOI: 10.1177/0394632015584724.

21. McDonnell M.J., Aliberti S., Goeminne P.C. et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir. Med. 2016; 4 (12): 969–979. DOI: 10.1016/S2213-2600(16)30320-4.

22. Du Q., Jin J., Liu X.et al. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: A systematic review and meta-analysis. PLoS One. 2016; 11 (3): e0150532. DOI: 10.1371/journal.pone.0150532.

23. Navaratnam V., Muirhead C.R., Hubbard R.B. et al. Critical care admission trends and outcomes in individuals with bronchiectasis in the UK. Q. J. Med. 2016; 109 (8): 523–526. DOI: 10.1093/qjmed/hcv206.

24. Navaratnam V., Millett E.R., Hurst J.R. et al. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax. 2017; 72 (2): 161–166. DOI: 10.1136/thoraxjnl-2015-208188.

25. Ringshausen F.C., de Roux A., Pletz M.W. et al. Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends. PLoS One. 2013; 8 (8): e71109. DOI: 10.1371/journal.pone.0071109.

26. Weycker D., Edelsberg J., Oster G. et al. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 2005; 12 (4): 205–209. DOI: 10.1097/01.cpm.0000171422.98696.ed.

27. Kwak H.J., Moon J.Y., Choi Y.W. et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J. Exp. Med. 2010; 222 (4): 237–242. DOI: 10.1620/tjem.222.237.

28. Quint J.K., Millett E.R., Joshi M. et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur. Respir. J. 2016; 47 (1): 186–193. DOI: 10.1183/13993003.01033-2015.

29. Chang A.B., Grimwood K., Mulholland E.K. et al. Bronchiectasis in Indigenous children in remote Australian communities. Med. J. Aust. 2002; 177 (4): 200–204.

30. Seitz A.E., Olivier K.N., Steiner C.A. et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest. 2010; 138 (4): 944–949. DOI: 10.1378/chest.10-0099.

31. Finklea J.D., Khan G., Thomas S. et al. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir. Med. 2010; 104 (6): 816–821. DOI: 10.1016/j.rmed.2009.11.021.

32. Goeminne P.C., Nawrot T.S., Ruttens D. et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir. Med. 2014; 108 (2): 287–296. DOI: 10.1016/j.rmed.2013.12.015.

33. de la Rosa D., Martinez-Garcia M.A., Olveira C. et al. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chron. Respir. Dis. 2016; 13 (4): 361–371. DOI: 10.1177/1479972316643698.

34. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung. 2006; 35 (1): 58–65. DOI: 10.1016/j.hrtlng.2005.04.003.

35. O’Donnell A.E., Barker A.F., Ilowite J.S. et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest. 1998; 113 (5): 1329–1334. DOI: 10.1378/chest.113.5.1329.

36. Barker A.F., O’Donnell A.E., Flume P. et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir. Med. 2014; 2 (9): 738–749. DOI: 10.1016/S2213-2600(14)70165-1.

37. Vendrell M., de Gracia J., Olveira C. et al. Normativa SEPAR: diagnóstico y tratamiento de las bronquiectasias. Arch. Bronconeumol. 2008; 44 (11): 629–640. DOI: 10.1016/S1579-2129(08)60117-2.

38. Pasteur M.C., Bilton D., Hill A.T., British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65 (Suppl. 1): i1–58. DOI: 10.1136/thx.2010.136119.

39. Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin. Microbiol. Infect. 2011; 17 (Suppl. 6): E1–59. DOI: 10.1111/j.1469-0691.2011.03672.x.

40. Andrews J.C., Schünemann H.J., Oxman A.D. et al. GRADE guidelines: 15. Going from evidence to recommendation–determinants of a recommendation’s direction and strength. J. Clin. Epidemiol. 2013; 66 (7): 726–735. DOI: 10.1016/j.jclinepi.2013.02.003.

41. Alonso-Coello P., Schünemann H.J., Moberg J. et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. Br. Med. J. 2016; 353: i2016. DOI: 10.1136/bmj.i2016.

42. Anwar G.A., McDonnell M.J., Worthy S.A. et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: A prospective observational cohort study. Respir. Med. 2013; 107 (7): 1001–1007. DOI: 10.1016/j.rmed.2013.04.013.

43. Shoemark A., Ozerovitch L., Wilson R. Aetiology in adult patients with bronchiectasis. Respir. Med. 2007; 101 (6): 1163–1170. DOI: 10.1016/j.rmed.2006.11.008.

44. Pasteur M.C., Helliwell S.M., Houghton S.J. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med 2000; 162 (4, Pt 1): 1277–1284. DOI: 10.1164/ajrccm.162.4.9906120.

45. Lonni S., Chalmers J.D., Goeminne P.C. et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann. Am. Thorac. Soc. 2015; 12 (12): 1764–1770. DOI: 10.1513/AnnalsATS.201507-472OC.

46. Greenberger P.A. When to suspect and work up allergic bronchopulmonary aspergillosis. Ann. Allergy Asthma Immunol. 2013; 111 (1): 1–4. DOI: 10.1016/j.anai.2013.04.014.

47. Knutsen A.P., Bush R.K., Demain J.G. et al. Fungi and allergic lower respiratory tract diseases. J. Allergy Clin. Immunol. 2012; 129 (2): 280–291. DOI: 10.1016/j.jaci.2011.12.970.

48. Griffith D.E., Aksamit T., Brown-Elliott B.A. et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007; 175 (4): 367–416. DOI: 10.1164/rccm.200604-571ST.

49. Lucas J.S., Barbato A., Collins S.A. et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur. Respir. J. 2017; 49 (1): 1601090. DOI: 10.1183/13993003.01090-2016.

50. Bilton D., Henig N., Morrissey B. et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006; 130 (5): 1503–1510. DOI: 10.1378/chest.130.5.1503.

51. Murray M.P., Turnbull K., MacQuarrie S. et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur. Respir. J. 2009; 33 (2): 312–317. DOI: 10.1183/09031936.00122508.

52. Orriols R., Roe J. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic broncial infection by Pseudomonas aeruginosa. Respir. Med. 1999; 93 (7): 476–480.

53. McDonnell M.J., Jary H.R., Perry A. et al. Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir. Med. 2015; 109 (6): 716–726. DOI: 10.1016/j.rmed.2014.07.021.

54. Orriols R., Hernando R., Ferrer A. et al. Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration. 2015; 90 (4): 299–305. DOI: 10.1159/000438490.

55. White L., Mirrani G., Grover M. et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir. Med. 2012; 106 (3): 356–360. DOI: 10.1016/j.rmed.2011.11.018.

56. Goyal V., Chang A.B. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst. Rev. 2014; (6): CD010327. DOI: 10.1002/14651858.CD010327.pub2.

57. Steele K., Greenstone M., Lasserson J.A. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst. Rev. 2001; (1): CD002734. DOI: 10.1002/14651858.CD002734.

58. Lasserson T., Holt K. Oral corticosteroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst. Rev. 2001; (4): CD002162. DOI: 10.1002/14651858.CD002162.

59. Corless J.A., Warburton C.J. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst. Rev. 2000; (4): CD002174. DOI: 10.1002/14651858.CD002174.

60. Kapur N., Chang A.B. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst. Rev. 2007; (4): CD006427. DOI: 10.1002/14651858.CD006427.pub2.

61. Pizzutto S.J., Upham J.W., Yerkovich S.T. et al. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst. Rev. 2016; (1): CD007525. DOI: 10.1002/14651858.CD007525.pub3.

62. Tsang K.W., Tan K.C., Ho P.L. et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005; 60 (3): 239–243. DOI: 10.1136/thx.2002.003236.

63. Mandal P., Chalmers J.D., Graham C. et al. Atorvastatin as a stable treatment in bronchiectasis: A randomized controlled trial. Lancet Respir. Med. 2014; 2 (6): 455–463. DOI: 10.1016/S2213-2600(14)70050-5.

64. Hernando R., Drobnic M.E., Cruz M.J. et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int. J. Clin. Pharm. 2012; 34 (4): 644–650. DOI: 10.1007/s11096-012-9659-6.

65. Brodt A.M., Stovold E., Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur. Respir. J. 2014; 44 (2): 382–393. DOI: 10.1183/09031936.00018414.

66. Gao Y., Guan W., Xu G. et al. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. PLoS One. 2014; 9 (3): e90047. DOI: 10.1371/journal.pone.0090047.

67. Shi Z.L., Peng H., Hu X.W. et al. Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review. Pulm. Pharmacol. Ther. 2014; 28 (2): 171–178. DOI: 10.1016/j.pupt.2013.09.003.

68. Wu Q., Shen W., Cheng H. et al. Long-term macrolides for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Respirology. 2014; 19 (3): 321–329. DOI: 10.1111/resp.12233.

69. Zhuo G.Y., He Q., Xiang-Lian L. et al. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials. Pulm. Pharmacol. Ther. 2014; 29 (1): 80–88. DOI: 10.1016/j.pupt.2014.02.002.

70. Fan L.C., Lu H.W., Wei P. et al. Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials. BMC Infect. Dis. 2015; 27 (15): 160. DOI: 10.1186/s12879-015-0872-5.

71. Yang J.W., Fan L.C., Lu H.W. et al. Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis. Clin. Respir. J. 2016; 10 (6): 731–739. DOI: 10.1111/crj.12278.

72. Hnin K., Nguyen C., Carson K.V. et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst. Rev. 2015; (8): CD001392.DOI: 10.1002/14651858.CD001392.pub3.

73. Currie D.C., Garbett N.D., Chan K.L. et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q. J. Med. 1990; 76 (280): 799–816.

74. Cymbala A.A., Edmonds L.C., Bauer M.A. et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat. Respir. Med. 2005; 4 (2): 117–122.

75. Drobnic M.E., Suñé P., Montoro J.B. et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. 2005; 39 (1): 39–44. DOI: 10.1345/aph.1E099.

76. Murray M.P., Govan J.R.W., Doherty C.J. et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2011; 183 (4): 491–499. DOI: 10.1164/rccm.201005-0756OC.

77. Wong C., Jayaram L., Karalus N. et al. Azithromycin for prevention of exacerbations in non-cystic fi brosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 660–667. DOI: 10.1016/S0140-6736(12)60953-2.

78. Serisier D.J., Bilton D., De Soyza A. et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013; 68 (9): 812–817. DOI: 10.1136/thoraxjnl-2013-203207.

79. Serisier D.J., Martin M.L., McGuckin M.A. et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013; 309 (12): 1260–1267. DOI: 10.1001/jama.2013.2290.

80. Altenburg J. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non–cystic fibrosis bronchiectasis. JAMA. 2013; 309 (12): 1251–1259. DOI: 10.1001/jama.2013.1937.

81. De Diego A., Milara J., Martinez-Moragón E. et al. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology. 2013; 18 (7): 1056–1062. DOI: 10.1111/resp.12130.

82. Tabernero Huguet E., Gil Alaña P., Alkiza Basañez R. et al. [Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection]. Rev. Esp. Geriatr. Gerontol. 2015; 50 (3): 111–115. DOI: 10.1016/j.regg.2014.09.005 (in Spanish).

83. Haworth C.S., Foweraker J.E., Wilkinson P. et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2014; 189 (8): 975–982. DOI: 10.1164/rccm.201312-2208OC.

84. PROLONGED antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. Br. Med. J. 1957; 2 (5039): 255–259.

85. Lourdesamy A.I., Muthukumaru U. Efficacy of azithromycin in the treatment of bronchiectasis. Respirology. 2014; 19 (8): 1178–1182. DOI: 10.1111/resp.12375.

86. Liu J., Zhong X., He Z. et al. Effect of Low-Dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators Inflamm. 2014; 2014: 708608. DOI: 10.1155/2014/708608.

87. Barker A.F., Couch L., Fiel S.B. et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162 (2, Pt 1): 481–485. DOI: 10.1164/ajrccm.162.2.9910086.

88. Hart A., Sugumar K., Milan S.J. et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev. 2014; (5): CD002996. DOI: 10.1002/14651858.CD002996.pub3.

89. Wilkinson M., Sugumar K., Milan S.J. et al. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2014; (5): CD001289. DOI: 10.1002/14651858.CD001289.pub2.

90. Wills P., Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev. 2002; (2): CD002996. DOI: 10.1002/14651858.CD002996.

91. Nicolson C.H.H., Stirling R.G., Borg B.M. et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir. Med. 2012; 106 (5): 661–667. DOI: 10.1016/j.rmed.2011.12.021.

92. Kellett F., Robert N.M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 2011; 105 (12): 1831–1835. DOI: 10.1016/j.rmed.2011.07.019.

93. Bilton D., Daviskas E., Anderson D. et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013; 144 (1): 215–225. DOI: 10.1378/chest.12-1763.

94. Bilton D., Tino G., Barker A.F.,et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014; 69 (12): 1073–1079. DOI: 10.1136/thoraxjnl-2014-205587.

95. Vogelmeier C.F., Criner G.J., Martinez F.J. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur. Respir. J. 2017; 49 (3): 1700214. DOI: 10.1183/13993003.00214-2017.

96. Reddel H.K., Bateman E.D., Becker A. et al. A summary of the new GINA strategy: A roadmap to asthma control. Eur. Respir. J. 2015; 46 (3): 622–639. DOI: 10.1183/13993003.00853-2015.

97. Martínez-García M.Á., Soler-Cataluña J.J., Catalán-Serra P. et al. Clinical efficacy and safety ofbudesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012; 141 (2): 461–468. DOI: 10.1378/chest.11-0180.

98. Fan L.C., Liang S., Lu H.W. et al. Efficiency and safety of surgical intervention to patients with non-cystic fibrosis bronchiectasis: a meta-analysis. Sci. Rep. 2015; 2 (5): 17382. DOI: 10.1038/srep17382.

99. Hiramatsu M., Shiraishi Y., Nakajima Y. et al. Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. Ann. Thorac. Surg. 2012; 93 (1): 245–250. DOI: 10.1016/j.athoracsur.2011.08.077.

100. Hoffman E. The late results of the conservation of the apical segment of the lower lobe in resections for bronchiectasis. Thorax. 1955; 10 (2): 137–141. DOI: 10.1136/thx.10.2.137.

101. Collis J. Fate of the lower apical segment in resections for bronchiectasis. Thorax. 1953; 8 (4): 323–325. DOI: 10.1136/thx.8.4.323.

102. Tanaka H., Matsumura A., Okumura M. et al. Pneumonectomy for unilateral destroyed lung with pulmonary hypertension due to systemic blood flow through broncho-pulmonary shunts. Eur. J. Cardiothorac. Surg. 2005; 28 (3): 389–393. DOI: 10.1016/j.ejcts.2005.04.044.

103. Gourin A., Garzon A.A. Operative treatment of massive hemoptysis. Ann. Thorac. Surg. 1974; 18 (1): 52–60.

104. Schneiter D., Meyer N., Lardinois D. et al. Surgery for non-localized bronchiectasis. Br. J. Surg. 2005; 92 (7): 836–839. DOI: 10.1002/bjs.4949.

105. Zhang P., Zhang F., Jiang S. et al. Video-assisted thoracic surgery for bronchiectasis. Ann. Thorac. Surg. 2011; 91 (1): 239–243. DOI: 10.1016/j.athoracsur.2010.08.035.

106. Lee A.L., Burge A.T., Holland A.E. Airway clearance techniques for bronchiectasis. Cochrane Database Syst. Rev. 2015; (11): CD008351. DOI: 10.1002/14651858.CD008351.pub3.

107. Bradley J., Moran F., Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst. Rev. 2002; (2): CD002166. DOI: 10.1002/14651858.CD002166.

108. Guimarães F.S., Moço V.J.R., Menezes S.L.S. et al. Effects of ELTGOL and Flutter VRP1® on the dynamic and static pulmonary volumes and on the secretion clearance of patients with bronchiectasis. Rev. Bras. Fisioter. 2012; 16 (2): 108–113. DOI: 10.1590/S1413-35552012005000016.

109. Nicolini A., Cardini F., Landucci N. et al. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm. Med. 2013; 4 (13): 21. DOI: 10.1186/1471-2466-13-21.

110. Eaton T., Young P., Zeng I. et al. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron. Respir. Dis. 2007; 4 (1): 23–30. DOI; 10.1177/1479972306074481.

111. Naraparaju S., Vaishali K., Venkatesan P. et al. A comparison of the Acapella and a threshold inspiratory muscle trainer for sputum clearance in bronchiectasis – a pilot study. Physiother. Theory Pract. 2010; 26 (6): 353–357. DOI: 10.3109/09593981003596616.

112. Figueiredo P.H., Zin W.A., Guimarães F.S. Flutter valve improves respiratory mechanics and sputum production in patients with bronchiectasis. Physiother. Res. Int. 2012; 17 (1): 12–20. DOI: 10.1002/pri.507.

113. Patterson J.E., Bradley J.M., Hewitt O. et al. Airway clearance in bronchiectasis: A randomized crossover trial of active cycle of breathing techniques versus acapella? Respiration. 2005; 72 (3): 239–242. DOI: 10.1159/000085363.

114. Murray M.P., Pentland J.L., Hill A.T. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2009; 34 (5): 1086–1092. DOI: 10.1183/09031936.00055509.

115. Faulkner J., Gerhard J., Stoner L. et al. Self-paced walking within a diverse topographical environment elicits an appropriate training stimulus for cardiac rehabilitation patients. Rehabil. Res. Pract. 2012; 2012: 140871. DOI: 10.1155/2012/140871.

116. Lee A.L., Hill C.J., Cecins N. et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis – a randomised controlled trial. Respir. Res. 2014; 15 (15): 44. DOI: 10.1186/1465-9921-15-44.

117. Zanini A., Aiello M., Adamo D. et al. Effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: a retrospective analysis of clinical and functional predictors of efficacy. Respiration. 2015; 89 (6): 525–533. DOI: 10.1159/000380771.

118. Bradley J., Moran F., Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst. Rev. 2002; (3): CD002166. DOI: 10.1002/14651858.CD002166.

119. Lee A.L., Hill C.J., McDonald C.F. et al. Pulmonary rehabilitation in individuals with non-cystic fibrosis bronchiectasis: a systematic review. Arch. Phys. Med. Rehabil. 2017; 98 (4): 774–782.e1. DOI: 10.1016/j.apmr.2016.05.017.

120. Patterson J.E., Bradley J.M., Elborn J.S. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques (incorporating postural drainage and vibration) versus test of incremental respiratory endurance. Chron. Respir. Dis. 2004; 1 (3): 127–130. DOI: 10.1191/1479972304cd034oa.

121. Gokdemir Y., Karadag-Saygi E., Erdem E. et al. Comparison of conventional chest physiotherapy and high-frequency chest wall oscillation in primary ciliary dyskinesia. Pediatr. Pulmonol. 2014; 49 (6): 611–616. DOI: 10.1002/ppul.22861.

122. Mandal P., Sidhu M.K., Kope L. et al. A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis. Respir. Med. 2012; 106 (12): 1647–1654. DOI: 10.1016/j.rmed.2012.08.004.

123. Newall C., Stockley R.A., Hill S.L. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax. 2005; 60 (11): 943–948. DOI: 10.1136/thx.2004.028928.

124. Liaw M.Y., Wang Y.H., Tsai Y.C. et al. Inspiratory muscle training in bronchiectasis patients: a prospective randomized controlled study. Clin. Rehabil. 2011; 25 (6): 524–536. DOI: 10.1177/0269215510391682.

125. Aliberti S., Masefield S., Polverino E. et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur. Respir. J. 2016; 48 (3): 632–647. DOI: 10.1183/13993003.01888-2015.

126. Wilson C.B., Jones P.W., O’Leary C.J. et al. Validation of the St. George’s respiratory questionnaire in bronchiectasis. Am. J. Respir. Crit. Care Med. 1997; 156 (2, Pt 1): 536–541. DOI: 10.1164/ajrccm.156.2.9607083.

127. Quittner A.L., O‘Donnell A.E., Salathe M.A. et al. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015; 70 (1): 12–20. DOI: 10.1136/thoraxjnl-2014-205918.

128. Martínez-García M.A., Soler-Cataluña J.J., Perpiñá-Tordera M. et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007; 132 (5): 1565–1572. DOI: 10.1378/chest.07-0490.

129. Chalmers J.D., Aliberti S., Blasi F. Management of bronchiectasis in adults. Eur. Respir. J. 2015; 45 (5): 1446–1462. DOI: 10.1183/09031936.00119114.

130. Goeminne P.C., Scheers H., Decraene A. et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir. Res. 2012; 16 (13): 21. DOI: 10.1186/1465-9921-13-21.

131. Hill A.T., Haworth C.S., Aliberti S. et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur. Respir. J. 2017; 49 (6): 1700051. DOI: 10.1183/13993003.00051-2017.

132. Spinou A., Siegert R.J., Guan W.J. et al. The development and validation of the bronchiectasis health questionnaire. Eur. Respir. J. 2017; 49 (5): 1601532. DOI: 10.1183/13993003.01532-2016.


Дополнительные файлы

Для цитирования: Редакционная с. Бронхоэктазы у взрослых больных: клинические рекомендации Европейского респираторного общества.  Пульмонология. 2018;28(2):147-168. https://doi.org/10.18093/0869-0189-2018-28-2-147-168

For citation: Editorial a. Adult patients with bronchiectasis: clinical guideline of European Respiratory Society. Russian Pulmonology. 2018;28(2):147-168. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-2-147-168

Просмотров: 504

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)